<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">MECLOFENAMATE SODIUM</span><br/>(me-kloe-fen-am'ate)<br/><span class="topboxtradename">Meclofen, </span><span class="topboxtradename">Meclomen<br/></span><b>Classifications:</b> <span class="classification">central nervous system agent</span>; <span class="classification">analgesic</span>; <span class="classification">nsaid</span>; <span class="classification">antipyretic</span><br/><b>Prototype: </b>Ibuprofen<br/><b>Pregnancy Category: </b> B  (D in third trimester)<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>50 mg, 100 mg capsules</p>
<h1><a name="action">Actions</a></h1>
<p>Action mechanism unclear, but thought to inhibit prostaglandin synthesis and competition for binding at prostaglandin receptor
         sites. Does not appear to alter course of arthritis.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Palliative antiinflammatory, analgesic, and antipyretic activity.</p>
<h1><a name="uses">Uses</a></h1>
<p>Symptomatic treatment of acute or chronic rheumatoid arthritis and osteoarthritis. Also in combination with gold salts or
         corticosteroids in treatment of rheumatoid arthritis.
      </p>
<h1><a name="unlabeleduses">Unlabeled Uses</a></h1>
<p>Management of psoriatic arthritis, mild to moderate postoperative pain, dysmenorrhea.</p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Patient in whom bronchospasm, urticaria, and allergic rhinitis are induced by aspirin or other <small>NSAID</small>s; pregnancy [first trimester (category B) and third trimester (category D)], lactation, children 
      </p><h1><a name="precaution">Cautious Use</a></h1>
<p>History of upper GI tract disease; compromised cardiac and kidney function, or other conditions predisposing to fluid retention.</p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Inflammatory Disease</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 200400 mg/d in 34 divided doses (max: 400 mg/d)<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Oral</span><br/><ul>
<li>Give with food or milk if patient complains of GI distress. An aluminum and magnesium hydroxide antacid (Maalox) also may
            be prescribed. Consult physician if symptoms persist.
         </li>
<li>Withhold dose and report to physician if significant diarrhea occurs.</li>
<li>Store at 15°30° C (59°86° F) in airtight, light-resistant container.</li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">CNS:</span> <span class="speceff-common">Dizziness,</span> vertigo, lack of concentration, confusion, <span class="speceff-common">headache,</span> tinnitus. <span class="typehead">CV:</span> Edema. <span class="typehead">GI:</span> <span class="speceff-common">Severe diarrhea (dose-related),</span> peptic ulceration, <span class="speceff-life">GI bleeding</span>, dyspepsia, abdominal pain, <span class="speceff-common">nausea,</span> vomiting (may be severe), flatulence, eructation, pyrosis, anorexia, constipation. <span class="typehead">GI:</span> <span class="speceff-common">Abnormal liver function tests,</span> cholestatic jaundice. <span class="typehead">Special Senses:</span> Blurred vision. <span class="typehead">Urogenital:</span> Elevated BUN and creatinine, kidney failure. <span class="typehead">Skin:</span> Rash, pruritus, urticaria. 
      <h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span> <span class="classification">oral anticoagulants</span>, <b>heparin</b> may prolong bleeding time; may increase <b>lithium</b> toxicity; increases pharmacologic and toxic activity of <b>phenytoin,</b> <span class="classification">sulfonylureas</span>, <span class="classification">sulfonamides</span>, <b>warfarin</b> through protein-binding displacement. <span class="typehead">Herbal:</span> <b>Feverfew,</b> <b>garlic,</b> <b>ginger,</b> <b>ginkgo</b> increase bleeding potential. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Absorption:</span> Rapidly and completely absorbed from GI tract. <span class="typehead">Peak:</span> 12 h. <span class="typehead">Duration:</span> 24 h. <span class="typehead">Distribution:</span> Crosses placenta. <span class="typehead">Metabolism:</span> Metabolized in liver. <span class="typehead">Elimination:</span> 60% excreted in urine, 30% in feces. <span class="typehead">Half-Life:</span> 23.3 h. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Expect clinical improvement in the rheumatoid patient within 23 wk with reduction in number of tender joints, severity
            of tenderness, and duration of morning stiffness.
         </li>
<li>Observe improvement in the osteoarthritic patient as reflected by reduced night pain, pain on walking, starting pain, and
            pain with passive motion and improved joint function.
         </li>
<li>Report diarrhea promptly. It is the most frequent adverse effect and usually dose related.</li>
<li>Lab tests: Monitor kidney function where incidence of adverse reactions is potentially high because drug is excreted primarily
            by the kidneys. Monitor PT, PTT, and INR frequently with concurrent anticoagulant therapy.
         </li>
<li>Monitor I&amp;O ratio. Encourage fluid intake of at least 8 glasses of liquid a day.</li>
<li>Consider sodium content of meclofenamate tablets if patient is on restricted sodium intake.</li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Stop taking drug and promptly notify the physician if nausea, vomiting, severe diarrhea, and abdominal pain occur. Generally
            dose reduction or temporary withdrawal will control symptoms.
         </li>
<li>Report to physician without delay: Blurred vision, tinnitus, or taste disturbances.</li>
<li>Schedule ophthalmic examinations before and periodically during treatment and whenever you experience visual disturbances.</li>
<li>Notify physician if you become pregnant.</li>
<li>Weigh under standard conditions (similar clothing, same time of day) twice weekly. Report weight gain of more than 2.5 to
            3.5 kg (34 lb)/wk as well as signs of edema: Swollen ankles, tibiae, hands, feet.
         </li>
<li>Do not use OTC drugs without approval of physician.</li>
<li>Dizziness, a troublesome early side effect, frequently disappears in time. Avoid driving a car or potentially hazardous activities
            until response to drug is known.
         </li>
<li>Report immediately to physician any sign of bleeding (e.g., melena, epistaxis, ecchymosis) when taking concomitant oral anticoagulant.</li>
<li>Do not breast feed while using this drug.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>